Drugs / Melanoma antigens-specific CD8+ T lymphocytes
Melanoma antigens-specific CD8+ T lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02424916 | May 2015 → May 2019 | metastatic melanoma | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Melanoma antigens-specific CD8+ T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02424916 ↗ |
| Modality | Cell therapy | “The intervention uses an autologous somatic cell therapy medicinal product.” NCT02424916 ↗ |
| Route | Intravenous | “intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes” NCT02424916 ↗ |